Lupin's US arm enters into USD 30 million settlement agreement with Humana
Lupin Pharmaceuticals' US subsidiary settled with Humana for $30 million to resolve antitrust allegations, while maintaining its denial of wrongdoing.Summary
Lupin Pharmaceuticals, Inc. USA (LPI), a subsidiary of Lupin, has reached a $30 million settlement agreement with Humana Inc. to resolve claims of anticompetitive behavior and violations of antitrust laws. The case was part of the larger “In Re Generic Pharmaceuticals Antitrust Litigation” in Philadelphia, Pennsylvania. While LPI denies the allegations, the company opted to settle to avoid further legal costs and uncertainties, especially given recent settlements by other defendants. The agreement provides for a full and final release of all claims against LPI and its affiliates by Humana. Lupin clarified that the settlement amount was already factored into its previous financial results and that the agreement does not constitute an admission of liability.
(Source：Business Standard)